These findings suggest that the TGF‐β receptor inhibitor improves the localization of tumor‐infiltrated CD8+ T cells within the tumor both directly by reducing CXCR4 expression on these cells, and indirectly by modulating CAF activity. The gene discussed is CXCR4; the disease is neoplasm.